Lewy bodies (LBs) are hallmark intracellular inclusions characteristic of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). These proteinaceous aggregates primarily consist of alpha-synuclein (α-syn) along with numerous other proteins, lipids, and cellular components. Understanding Lewy body formation is crucial for elucidating PD pathogenesis and developing disease-modifying therapies.
¶ Lewy Body Biology
¶ Morphology and Classification
flowchart TD
A["Lewy Body Formation"] --> BSoluble α-S["yn Monomers"]
B --> Cα-S["yn Misfolding"]
C --> D["Oligomeric Intermediates"]
D --> E["Protofibrils"]
E --> F["Fibrillar Aggregates"]
F --> G["Lewy Bodies"]
G --> H["Classical LBs"]
G --> I["Cortical LBs"]
G --> J["Incidental LBs"]
| Type |
Location |
Characteristics |
| Classical (Brainstem) |
Substantia nigra, locus coeruleus |
Dense core, halos, ubiquitin-positive |
| Cortical |
Cerebral cortex |
Diffuse, less organized |
| Transitional |
Limbic system |
Intermediate features |
- Core: Densely packed, 8-10 nm diameter fibrils
- Halo: Radiating fibrils, 80-200 nm wide
- Membranous organelles: Mitochondria, lysosomes, ER fragments
- Lipid membranes: Disrupted cellular membranes
Alpha-Synuclein
- Principal component (up to 95% of protein mass)
- Post-translational modifications: phosphorylation (Ser129), ubiquitination, nitration
- Conformations: monomeric, oligomeric, fibrillar
Associated Proteins
| Protein |
Role |
Significance |
| Ubiquitin |
Protein degradation tag |
Ubiquitinated in LBs |
| p62/SQSTM1 |
Selective autophagy receptor |
Autophagy-lysosome pathway |
| Parkin |
E3 ubiquitin ligase |
Genetic link to PD |
| Synphilin-1 |
α-Syn interacting protein |
Co-aggregation |
| Tubulin |
Cytoskeletal protein |
Fibril organization |
| Neurofilaments |
Cytoskeletal proteins |
Structural components |
- Phospholipids: From disrupted membranes
- Gangliosides: GM1, GM3 alterations
- Cholesterol: Altered metabolism
- Primary nucleation: Spontaneous α-syn monomer conversion
- Secondary nucleation: Fibril surface catalyzes new aggregates
- Oligomer formation: Toxic intermediate species
- Fibril elongation: Template-directed polymerization
- Maturation: Formation of Lewy bodies
flowchart LR
subgraph "Aggregation Triggers"
A["Genetic Mutations"] --> D["Aggregation"]
B["Oxidative Stress"] --> D
C["Protein Clearance Defects"] --> D
end
subgraph "Aggregation Process"
D --> E["Misfolding"]
E --> F["Oligomerization"]
F --> G["Fibrillization"]
end
subgraph "Clearance Mechanisms"
H["Proteasome"] -.-> D
I["Autophagy"] -.-> D
Jchaperones["Jchaperones"] -.-> D
end
SNCA Multiplications
- Gene duplication/triplication causes familial PD
- Dose-dependent disease severity
- Confirms α-syn as disease driver
Point Mutations
- A53T, A30P, E46K, H50Q, G51D
- Alter aggregation kinetics
- Enhance fibril formation
- Oxidative stress: ROS modify α-syn, promoting aggregation
- Metal ions: Iron, copper catalyze oxidation
- Pesticides: Rotenone, MPTP exposure
- Traumatic brain injury: Increases LB formation risk
The Braak staging hypothesis proposes that pathological α-syn spreads:
- Stage 1-2: Lower brainstem (dorsal motor nucleus)
- Stage 3-4: Midbrain (substantia nigra)
- Stage 5-6: Forebrain, cortex
- Synaptic transmission: α-syn release and uptake
- Tunneling nanotubes: Direct cell-to-cell transfer
- Extracellular vesicles: Exosome-mediated spread
- Inflammation: Microglial spread
¶ Lewy Bodies and Neurodegeneration
Loss of Function
- Impaired synaptic vesicle recycling
- Mitochondrial dysfunction
- Endoplasmic reticulum stress
- Lysosomal dysfunction
Gain of Toxic Function
- Pore-like oligomers
- Mitochondrial permeabilization
- Calcium dysregulation
- Oxidative stress generation
- Brainstem LBs: Motor symptoms (tremor, bradykinesia)
- Limbic LBs: Mood, autonomic dysfunction
- Cortical LBs: Cognitive impairment, hallucinations
| Approach |
Mechanism |
Status |
| Small molecule inhibitors |
Prevent oligomerization |
Research |
| Anti-α-syn antibodies |
Clear aggregated protein |
Clinical trials |
| Gene therapy |
Reduce α-syn expression |
Preclinical |
| ** chaperones** |
Stabilize native state |
Investigational |
- Autophagy enhancers: Rapamycin, trehalose
- Proteasome activators: Research
- Immunotherapy: Active and passive vaccination
- Prasinezumab: Anti-α-syn antibody (Phase 2)
- Cinpanemab: Anti-α-syn antibody (Phase 2)
- APO-α-syn: Gene therapy approach